Microbot Medical Files 8-K

TL;DR

Microbot Medical filed an 8-K, check for updates.

AI Summary

Microbot Medical Inc. filed an 8-K on September 17, 2024, to report on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates that Microbot Medical Inc. has submitted a current report to the SEC, which may contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

• Microbot Medical Inc. (company) — Registrant
• September 17, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 000-19871 (filing_number) — Commission File Number
• 94-3078125 (tax_id) — IRS Employer Identification No.
• 288 Grove Street , Suite 388 Braintree , MA 02184 (address) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark

Filing Documents

• form8-k.htm (8-K) — 42KB
• ex99-1.htm (EX-99.1) — 13KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001493152-24-036539.txt ( ) — 237KB
• mbot-20240917.xsd (EX-101.SCH) — 3KB
• mbot-20240917_lab.xml (EX-101.LAB) — 33KB
• mbot-20240917_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 17, 2024, Microbot Medical Inc. (the "Company") issued a press release announcing, among other things, that it has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling and completing the follow up of 50% of the patients participating in the trial to evaluate the LIBERTY Endovascular Robotic Surgical System. The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

01 Other Events

Item 8.01 Other Events. The Company has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling and completing the follow up of 50% of the patients participating in the trial to evaluate the LIBERTY Endovascular Robotic Surgical System. The Company expects to complete enrollment and follow up in the fourth quarter of 2024 and file its 510(k) submission with the U.S. Food and Drug Administration (FDA) by the end of 2024. In parallel to conducting the pivotal human clinical trial, we have submitted our biocompatibility results to the FDA, as required by our IDE application. Forward Looking Statements This Item 8.01 of this Current Report on Form 8-K may contain "forward-looking statements." Such statements which are not purely historical (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "intends," "would," "could" and "estimates") are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, regulatory milestones. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company's reports and statements filed from time-to-time with the Securities and Exc

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. By: /s/ Harel Gadot Name: Harel Gadot Title: Chief Executive Officer, President and Chairman Date: September 17, 2024

View Full Filing

View this 8-K filing on SEC EDGAR